Skip to ContentSkip to Navigation
breed in kennis  -  sterk in techniek
Over ons Praktische zaken Waar vindt u ons prof. dr. H.J. (Hiddo) Lambers Heerspink

Publicaties

Adolescents With Type 1 Diabetes Using Dapagliflozin as an Adjunct-to-Insulin: Perspectives on Experiences of Clinical Trial Participation

A Dose of Perspective: A Multinational Survey of Patient and Clinician Views on Combination Therapy in CKD

A Hierarchical Composite Endpoint for Chronic Kidney Disease Progression in Patients with Focal Segmental Glomerulosclerosis

A meta-analysis of albuminuria as a surrogate endpoint for kidney failure

Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy

Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT-1 Over 176 Weeks

Association of UACR and UPCR with kidney failure: a pooled analysis of clinical trials

Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Authors' Reply: Convergent Proteinuria Reduction across Distinct Therapeutic Pathways in IgA Nephropathy

Pers/media

This drug could help millions keep their kidneys working longer

HMN 2026: How Kidney drug finerenone may help millions more patients after three major studies

Geen voordeel van lage dosis rivaroxaban bij patiënten met gevorderde nierschade

Onderzoek UMCG: finerenone werkt ook goed bij grote groep patiënten met chronische nierschade

The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum

Finerenone Improves UACR in T1D, CKD

'Nieuw' medicijn vermindert nierschade bij diabetespatiënten

Sustainable Development Goals

SDG 3 – Goede gezondheid en welzijnSDG 9 – Industrie, innovatie en infrastructuurSDG 16 – Vrede, rechtvaardigheid en sterke instellingen

Meer informatie over de Sustainable Development Goals.